AA
APLT

AlphaCentric Advisors’s Applied Therapeutics APLT Stock Holding History

AlphaCentric Advisors’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,000
Closed -$619K – 214
2021
Q1 		$619K Buy
+33,000
New +$712K 0.21% 37

Other funds holding APLT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

AlphaCentric Advisors's APLT Position: Q2 2021 in Review

AlphaCentric Advisors sold out of Applied Therapeutics (APLT) in Q2 2021, closing a stake of 33,000 shares — an estimated $619K sold.

AlphaCentric Advisors first reported a position in APLT in Q1 2021 and held it in 1 quarter. The position peaked at $619K in Q1 2021. 69 funds tracked by Wall St. Rank hold APLT as of Q2 2021.

  • AlphaCentric Advisors reported no remaining Applied Therapeutics position as of Q2 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 33,000 Applied Therapeutics shares in Q2 2021, an estimated $619K.
  • AlphaCentric Advisors first reported a position in Applied Therapeutics in Q1 2021 and held it in 1 quarter.
  • AlphaCentric Advisors's Applied Therapeutics position peaked at $619K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2021.

Based on AlphaCentric Advisors's 13F filing for Q2 2021, filed 9 Mar 2022.